Clinical Trial Update: A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) [Phase 3]

View source ↗

Summary

This document reports an ongoing Phase 3 clinical trial evaluating pembrolizumab with or without Sacituzumab Tirumotecan (MK-2870) in adults with resectable non…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Sacituzumab Tirumotecan (Sacituzumab govitecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: RECRUITING